Literature DB >> 14402

Pathophysiology of propranolol in hypertension.

E D Frohlich.   

Abstract

Only recently approved for use in the treatment of hypertension in the US, the beta-adrenergic receptor blocking compound propranolol has been used elsewhere for this purpose since 1964. The exact mechanisms to explain why and how "beta-blocking drugs" reduce arterial pressure are not known with certainty, but possible explanations include: (1) "resetting" of the baroreceptors, (2) reduction of cardiac output, (3) adaptation of circulation ("autoregulation"), (4) inhibition of renin release, (5) central nervous system effects, (6) possible antihypertensive metabolites, and (7) other unknown mechanisms or a combination of known mechanisms. Propranolol alone has been demonstrated to be extremely effective in reducing arterial pressure. In addition, the combination of propranolol and vasodilator and diuretic drugs would be expected to reduce vascular resistance without reflexive cardiac stimulation and with prevention of sodium and fluid retention.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 14402     DOI: 10.1097/00007611-197701000-00045

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  1 in total

1.  New indication for therapeutic potential of an old well-known drug (propranolol) for multiple myeloma.

Authors:  Ilknur Kozanoglu; Melis Kartal Yandim; Zeynep Birsu Cincin; Hakan Ozdogu; Bedia Cakmakoglu; Yusuf Baran
Journal:  J Cancer Res Clin Oncol       Date:  2012-10-19       Impact factor: 4.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.